Neeraj Agarwal, MD:In the CABOSUN trial, which was a phase II randomized trial of almost 160 patients comparing cabozantinib with sunitinib, cabozantinib was clearly superior to sunitinib in terms of progression-free survival, which was also confirmed by independent radiological assessment. The progression-free survival with cabozantinib was 8.6 months compared with 5.3 months for sunitinib. And this was a relatively high-risk patient population with only intermediate- and poor-risk patients being included, butmore notably—30% of patients had bone metastases. So, after confirming superiority of cabozantinib over sunitinib by an independent radiologic assessment, in my mind, cabozantinib is a drug of choice for this patient.
Going back to the question of sunitinib versus pazopanib, I did not choose pazopanib in this patient, because we already have data from the COMPARZ trial from a few years ago, where sunitinib was found to be equivalent to pazopanib or vice versa, as far as progression-free survival was concerned. So, we know that pazopanib and sunitinib are very comparable as far as progression-free survival is concerned, and cabozantinib is clearly superior to sunitinib from the CABOSUN trial. The extrapolation of the data basically leads me to believe that cabozantinib is also superior to pazopanib, with the caveat that these 2 drugs have not been compared head-to-head in a randomized clinical trial.
Transcript edited for clarity.
Case Scenario: A 73-year old female with rapidly progressing mRCC
March 2017
December 2017
George Discusses Potency of VEGF TKIs in Advanced Renal Cell Carcinoma
March 22nd 2024During a Case-Based Roundtable® event, Saby George, MD, discussed the case of a patient with clear cell renal cell carcinoma who progressed after left nephrectomy followed by treatment with axitinib plus pembrolizumab at recurrence.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Evolving Evidence Guides Treatment Selection for Favorable-Risk mRCC
March 6th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Rana McKay, MD, moderated a discussion on key takeaways from frontline combination trial data in patients with metastatic renal cell carcinoma. This is the second of 2 articles based on this event.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Guideline Recommendation Favors Doublet Over Triplet Therapy in ccRCC
February 28th 2024New guideline favors doublet therapy over triplet for metastatic renal clear cell cancer due to lower toxicity. COSMIC-313 trial shows improved progression-free survival with triplet therapy but significant adverse events.
Read More
Risk Groups Vital to Interpreting Results of RCC Immunotherapy Trials
February 21st 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Robert J. Motzer, MD, examined the impact of the CheckMate 214 and CheckMate 9ER trials of nivolumab/ipilimumab and nivolumab/cabozantinib in patients with advanced renal cell carcinoma. This is the first of 2 articles based on this event.
Read More